A Protocol of Irinotecan for Carcinoma of the Lung
Status:
Withdrawn
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The goal of this trial is to demonstrate the potential clinical benefit of irinotecan
chemotherapy in patients with a specific NSCLC phenotype, ISG15-positive. The use of
irinotecan in subjects with ISG15-positive NSCLC will be associated with an improved rate of
clinical benefit (objective response, disease stability, and time to progression) compared to
historical controls that were not previously selected for ISG-15 expression.